2-Methylthio-3-cyanothiophene | 116170-86-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-Methylthio-3-cyanothiophene
• 英文别名: 3-Thiophenecarbonitrile, 2-(methylthio)-；2-methylsulfanylthiophene-3-carbonitrile
• CAS: 116170-86-6
• 化学式: C₆H₅NS₂
• 分子量: 155.244
• InChiKey: CNRRZYYKTUYCNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  77.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  、 sodium hydroxide 、 4-氰基-5-甲硫基噻吩-2-甲酸乙酯 在 水 、 乙腈 、 2-噻吩甲酸 、 喹啉 、 Cu 、 乙醚 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.25h， 以2-Methylthio-3-cyanothiophene is obtained in a yield of 0.92 g as an oil的产率得到2-Methylthio-3-cyanothiophene
  参考文献：
  名称：

  Thio compounds having fungicidal activity

  摘要：

  本发明涉及一种新的硫化合物，其一般式为##STR1##其中R是一种烷基，它被卤素取代或未被取代，具有1-12个碳原子，或是一种具有2-4个碳原子的烯基或炔基，或是一种具有3或4个碳原子的烷二烯基，或是一种取代或未取代的苯基或苯基（C.sub.1-C.sub.4）烷基；R.sub.1是一种氰基，一种甲酰基，一种烷基羰基或烷氧羰基，它被卤素取代或未被取代，具有2-5个碳原子，或是一种取代或未取代的苯甲酰基，或是一种具有1-4个碳原子的烷基磺酰基；R.sub.2是一种氢原子，一种卤素原子，一种未被取代或取代了C.sub.1-C.sub.4烷基和C.sub.2-C.sub.5烷基羰基中的一种或两种基团的氨基，一种成为可能包括1或2个其他杂原子（选自N、O和S）的杂环环的氨基，一种具有1-4个碳原子的烷基或烷氧基，它可以被C.sub.2-C.sub.5烷基羰基取代或未取代，或是一种取代或未取代的苯基、苯氧基或苯硫基；或者其中R.sub.1和R.sub.2与它们所结合的乙烯基一起构成一种取代或未取代的苯基；X是一种氰基或甲酰基；n为1或2；Y是一种具有1-4个碳原子的烷基硫基；Z是一种氢原子、一种卤素原子、一种硝基或一种具有1-4个碳原子的烷基或烷氧基，它可以被卤素取代或未被取代；或者其中Y和Z一起构成一种硫原子；但是，当Y和Z不一起构成硫原子时，R.sub.1和R.sub.2与它们所结合的乙烯基一起构成一种取代或未取代的苯基。这些新的化合物表现出杀真菌和/或杀菌活性，特别适用于对抗植物病原体种子真菌和土壤真菌和/或细菌。

  公开号：

  US04994485A1

文献信息

• Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof
  申请人：BARBERIS Claude

  公开号：US20080146542A1

  公开（公告）日：2008-06-19

  The present invention concerns hydrazinocarbonyl-thieno[2,3- c ]pyrazoles of formula (I): wherein R1, R3, R4, are R5 are as defined in the disclosure; their preparation method, compositions containing the same and their use for the treatment of pathological conditions, in particular as anticancer agents.

  本发明涉及式(I)的联氮甲酰基噻吩[2,3-c]吡唑，其中R1、R3、R4和R5如本公开中所定义；它们的制备方法，含有它们的组合物以及它们用于治疗病理状况，特别是作为抗癌药物的用途。
• New thio compounds having fungicidal activity
  申请人：DUPHAR INTERNATIONAL RESEARCH B.V

  公开号：EP0234622A1

  公开（公告）日：1987-09-02

  The invention relates to new thio compounds of the general formula wherein R is an alkyl group substituted or not substituted with halogen and having 1-12 carbon atoms, an alkenyl or alkynyl group having 2-4 carbon atoms, an alkadienyl group having 3 or 4 carbon atoms or a substituted or unsubstituted phenyl or phenyl(C1-C4)alkyl group; R, is a cyano group, a formyl group, an alkylcarbonyl or alkoxycarbonyl group substituted or unsubstituted with halogen and having 2-5 carbon atoms, a substituted or unsubstituted benzoyl group, or an alkylsulphonyl group having 1-4 carbon atoms; R2 is a hydrogen atom, a halogen atom, an amino group unsubstituted or substituted with one or two group selected from C1-C4 alkyl and C2-C5 alkylcarbonyl, an amino group forming part of a heterocyclic ring which may comprise 1 or 2 additional heteroatoms selected from N, 0 and S, an alkyl or alkoxy group having 1-4 carbon atoms and optionally substituted with C2-C5 alkylcarbonyl, or a substituted or unsubstituted phenyl, phenoxy or phenylthio group; or wherein R, and Rz, together with the vinylene group to which they are bound, constitute a substituted or unsubstituted phenyl group; X is a cyano group or a formyl group; n is 1 or 2; Y is an alkylthio group having 1-4 carbon atoms; and Z is a hydrogen atom, a halogen atom, a nitro group, or an alkyl or alkoxy group having 1-4 carbon atoms and optionally substituted with halogen; or wherein Y and Z together constitute a sulphur atom; with the proviso that, when Y and Z do not together constitute a sulphur atom, R1 and Rz, together with the vinylene group to which they are bound, constitute a substituted or unsubstituted phenyl group. The new compounds show a fungicidal and/or bactericidal activity and may be used in particular against plantpathogenic seed fungi and soil fungi and/or bacteria.

  本发明涉及通式如下的新硫代化合物 式中 R 是被卤素取代或未被卤素取代且具有 1-12 个碳原子的烷基、具有 2-4 个碳原子的烯基或炔基、具有 3 或 4 个碳原子的烷二烯基或被取代或未被取代的苯基或苯基（C1-C4）烷基； R，是氰基、甲酰基、被卤素取代或未被卤素取代且具有 2-5 个碳原子的烷基羰基或烷氧羰基、被取代或未被取代的苯甲酰基或具有 1-4 个碳原子的烷基磺酰基； R2 是氢原子、卤素原子、未取代的或被 1 个或 2 个选自 C1-C4 烷基和 C2-C5 烷基羰基取代的氨基、构成杂环一部分的氨基（该杂环可包括 1 个或 2 个选自 N、0 和 S 的额外杂原子）、具有 1-4 个碳原子且任选被 C2-C5 烷基羰基取代的烷基或烷氧基、或取代或未取代的苯基、苯氧基或苯硫基； 或 其中 R 和 Rz 与它们结合的乙烯基一起构成取代或未取代的苯基； X 是氰基或甲酰基； n 是 1 或 2； Y 是具有 1-4 个碳原子的烷硫基；以及 Z 是氢原子、卤素原子、硝基或具有 1-4 个碳原子并可选择被卤素取代的烷基或 烷氧基； 或其中 Y 和 Z 共同构成一个硫原子；但当 Y 和 Z 不共同构成一个硫原子时，R1 和 Rz 与它们所结合的乙烯基共同构成一个取代或未取代的苯基。 新化合物具有杀真菌和/或杀细菌的活性，尤其可用于防治植物病原性种子真菌和土壤真菌和/或细菌。
• Gamma-diketones as wnt/β-catenin signaling pathway activators
  申请人：Samumed, LLC

  公开号：US11034682B2

  公开（公告）日：2021-06-15

  The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

  本公开提供了γ-二酮或其类似物，它们能激活Wnt/β-catenin信号转导，从而治疗或预防与信号转导有关的疾病，如骨质疏松症和骨关节病；成骨不全症、骨缺损、骨折、牙周病、耳硬化症、伤口愈合、颅面缺损、溶瘤性骨病、脑外伤或脊柱损伤、脑萎缩/与中枢神经系统分化和发育有关的神经系统疾病，包括帕金森病、中风、缺血性脑病、癫痫、阿尔茨海默病、抑郁症、躁狂症、精神分裂症；耳部疾病，如耳蜗毛细胞缺失；眼部疾病，如老年性黄斑变性、糖尿病性黄斑水肿或视网膜色素变性；以及与干细胞分化和生长有关的疾病，如脱发、造血相关疾病和组织再生相关疾病。
• GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS
  申请人：Samumed, LLC

  公开号：US20200223834A1

  公开（公告）日：2020-07-16

  The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
• US4994485A
  申请人：——

  公开号：US4994485A

  公开（公告）日：1991-02-19